Literature DB >> 26238205

Effect of DR4 promoter methylation on the TRAIL-induced apoptosis in lung squamous carcinoma cell.

Wenwu Wang1, Xiaoyan Qi2, Minghua Wu1.   

Abstract

The aim of the present study was to examine the relationship between DR4 methylation status and gene expression and to determine whether DR4 methylation status affects TRAIL-induced apoptosis in lung squamous carcinoma cells. MSP, RT-PCR and western blot analysis were applied to detect the methylation status and gene expression. An MTT assay was used to detect the cell proliferation inhibition rate and flow cytometry was utilized to detect the apoptotic rate. The results showed that there was no association of the apoptotic rate with the clinicopathological characteristics for 80.6% of 36 lung squamous carcinoma patients in the methylation status (P>0.05). In the lung squamous carcinoma patients, the probability of DR4 low expression was approximately 58.3%, which may be associated with DR4 promoter methylation. The results also showed that a low expression of DR4 was correlated with the prognosis of patients. The in vitro experiments suggested DR4 genes of H226 and SK-MES-1 cells were in the methylation status and their mRNA and proteins had a low expression. Following intervention with 5-Aza-CdR, the DR4 genes of H226 and SK-MES-1 cells were in the unmethylation status and their mRNA and protein expression was significantly upregulated compared with the pre-interference ones, with differences being statistically significant (P<0.05). In addition, following interference with 5-Aza-CdR, H226 and SK-MES-1 cells became significantly sensitive to TRAIL (P<0.05). The results revealed 5-Aza‑CdR was able to reverse DR4 methy-lation status to upregulate its expression, thereby increasing the TRAIL-induced apoptosis in lung squamous carcinoma cells. Therefore, combining 5-Aza-CdR and TRAIL is a new strategy for treating lung squamous carcinoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26238205     DOI: 10.3892/or.2015.4170

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

Review 1.  The Janus Face of Death Receptor Signaling during Tumor Immunoediting.

Authors:  Eimear O' Reilly; Andrea Tirincsi; Susan E Logue; Eva Szegezdi
Journal:  Front Immunol       Date:  2016-10-31       Impact factor: 7.561

Review 2.  The Role of TRAIL/DRs in the Modulation of Immune Cells and Responses.

Authors:  Duygu Sag; Zeynep Ozge Ayyildiz; Sinem Gunalp; Gerhard Wingender
Journal:  Cancers (Basel)       Date:  2019-09-30       Impact factor: 6.639

3.  Bacteria-derived ferrichrome inhibits tumor progression in sporadic colorectal neoplasms and colitis-associated cancer.

Authors:  Takuya Iwama; Mikihiro Fujiya; Hiroaki Konishi; Hiroki Tanaka; Yuki Murakami; Takehito Kunogi; Takahiro Sasaki; Keitaro Takahashi; Katsuyoshi Ando; Nobuhiro Ueno; Shin Kashima; Kentaro Moriichi; Hiroki Tanabe; Toshikatsu Okumura
Journal:  Cancer Cell Int       Date:  2021-01-06       Impact factor: 5.722

4.  A risk score system based on DNA methylation levels and a nomogram survival model for lung squamous cell carcinoma.

Authors:  Ming Zhang; Libing Sun; Yi Ru; Shasha Zhang; Junjun Miao; Pengda Guo; Jinghuan Lv; Feng Guo; Biao Liu
Journal:  Int J Mol Med       Date:  2020-04-27       Impact factor: 4.101

Review 5.  Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review.

Authors:  Gabriel B K Sasa; Cheng Xuan; Meiyue Chen; Zhenggang Jiang; Xianfeng Ding
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.